Filing Analysis
Alector, Inc. announced the termination of its collaboration agreement with GSK following failed clinical trials for latozinemab and nivisnebart. Additionally, the company fully repaid a $10.4 million loan to Hercules Capital.
🚩 Red Flags
- Termination of a major collaboration agreement with GSK (material loss of partnership/milestone potential).
- Recent history of clinical trial failures (Phase 3 failure in Oct 2025 and Phase 2 discontinuation in April 2026) leading to the termination.
- Significant cash outflow for loan repayment ($10.4M+) following major setbacks.
📋 Key Facts
- GSK terminated the Collaboration and License Agreement on July 6, 2026; termination effective January 2, 2027.
- Termination follows failure of Phase 3 INFRONT-3 trial (latozinemab) and discontinuation of Phase 2 PROGRESS-AD trial (nivisnebart).
- The Company repaid $10,428,827.77 in principal plus interest and prepayment charges to Hercules Capital on July 8, 2026.
- Loan Agreement dated November 14, 2024 was fully terminated.
Alector, Inc. reported the results of its 2026 annual meeting of stockholders held on June 17, 2026. The meeting included the election of Class II directors, the ratification of Ernst & Young LLP as the independent auditor, and a non-binding advisory vote on executive compensation.
📋 Key Facts
- Class II director nominees Elizabeth Garofalo, M.D., Errol De Souza, Ph.D., and Kristine Yaffe, M.D. were elected to serve until the 2029 annual meeting.
- Ernst & Young LLP was ratified as the independent registered accounting firm for the fiscal year ending December 31, 2026, with 97,717,750 votes in favor.
- The 'Say-on-Pay' advisory vote on executive compensation was approved with 58,652,335 votes for and 2,492,538 votes against.
Alector, Inc. entered into an at-the-market (ATM) sales agreement with TD Securities (USA) LLC to potentially sell up to $125 million of its common stock. The company intends to use any proceeds for general corporate purposes, including research, development, and manufacturing of its product candidates.
🚩 Red Flags
- Potential for significant shareholder dilution if the full $125 million is utilized.
- Reliance on equity markets to fund ongoing R&D and manufacturing operations.
📋 Key Facts
- Agreement entered on May 7, 2026, with TD Securities (USA) LLC (TD Cowen).
- Maximum aggregate offering price of $125,000,000 in common stock.
- TD Cowen will receive a commission of up to 3.0% of the gross sales price.
- The offering is conducted under an existing shelf registration statement on Form S-3 (File No. 333-294241).
- Alector is not obligated to sell any shares and can terminate the agreement with 10 days' notice.
Alector, Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were announced on May 7, 2026.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Alector, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The filing serves as a standard disclosure of the company's periodic financial performance via a press release.
📋 Key Facts
- Reported financial results for the quarter ended December 31, 2025, on February 25, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- Included Exhibit 99.1, which is the press release detailing the financial results.
Alector, Inc. announced the appointment of Neil Berkley as Chief Financial Officer, effective December 10, 2025. Mr. Berkley has been serving in an interim CFO capacity since June 2025 and will also continue his role as Chief Business Officer.
📋 Key Facts
- Neil Berkley appointed as Chief Financial Officer on December 10, 2025.
- Mr. Berkley has served as Interim CFO since June 2025.
- Mr. Berkley will maintain his current role as Chief Business Officer and principal financial officer.
- No changes were made to Mr. Berkley's existing compensatory arrangements.
Alector, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a formal notice that earnings results have been released via press release.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025
- Filing date: November 6, 2025
- The company is reporting under Item 2.02 (Results of Operations and Financial Condition)
- Financial results are contained in Exhibit 99.1
Alector is undergoing a major strategic pivot following the discontinuation of its Phase 3 INFRONT-3 clinical trial for latozinemab (AL001). This has triggered a massive workforce reduction of approximately 49% and the resignation of the President and Head of R&D.
🚩 Red Flags
- Failure of a Phase 3 clinical trial (INFRONT-3) for a lead product candidate.
- Massive workforce reduction (49% of staff) indicating significant downsizing/pivot.
- Departure of key executive (President and Head of R&D).
- Significant restructuring charges ($7.7M) impacting the balance sheet.
📋 Key Facts
- Discontinuation of the open-label extension portion of the INFRONT-3 trial and the continuation study for latozinemab (AL001).
- Workforce reduction plan impacting approximately 75 employees, representing ~49% of the company's staff.
- Estimated incremental restructuring charges of $7.7 million related to severance and termination benefits.
- Resignation of Dr. Sara Kenkare-Mitra, President and Head of R&D, effective December 22, 2025.
- The reduction in force is expected to be completed during the first half of 2026.
Alector, Inc. announced its quarterly financial results for the period ending June 30, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing incorporates an earnings press release as Exhibit 99.1
- Information under Item 2.02 and 9.01 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Alector, Inc. announced the resignation of its CFO, Dr. Marc Grasso, effective June 20, 2025. The company has appointed Neil Berkley as Interim CFO and Grace Wong-Sarad as Principal Accounting Officer.
🚩 Red Flags
- Sudden departure of the Chief Financial Officer (CFO) can sometimes signal internal friction or financial irregularities, though no restatement was mentioned here.
- Appointment of an 'Interim' CFO suggests a transition period rather than a permanent succession plan.
📋 Key Facts
- CFO Dr. Marc Grasso resigned on June 9, 2025, to pursue other opportunities; effective date is June 20, 2025.
- Neil Berkley (currently Chief Business Officer) appointed as Interim CFO and Principal Financial Officer.
- Grace Wong-Sarad (VP, Accounting) appointed as Principal Accounting Officer.
- Interim CFO Neil Berkley to receive a $91,000 retention bonus payable in December 2025.
- Principal Accounting Officer Grace Wong-Sarad to receive a $54,545 retention bonus payable in December 2025.
- Stockholders ratified Ernst & Young LLP as independent auditors for fiscal year ending Dec 31, 2025.
Alector, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: May 8, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Information under Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Alector, Inc. announced the resignation of its Chief Medical Officer, Dr. Gary Romano, effective April 25, 2025. The departure is stated to be for the purpose of pursuing other opportunities.
🚩 Red Flags
- Departure of a key C-suite executive (Chief Medical Officer) in a biotech company can impact clinical development momentum and investor confidence.
📋 Key Facts
- Dr. Gary Romano resigned as Chief Medical Officer on March 25, 2025.
- The resignation becomes effective on April 25, 2025.
- Dr. Romano has served in the role since May 2022.
Alector, Inc. announced a workforce reduction of approximately 13% (25 employees) as part of a cost-reduction initiative to align resources with preclinical and research priorities. The company expects one-time restructuring charges of roughly $2.4 million.
🚩 Red Flags
- Workforce reduction (13%) indicates a strategic pivot or need for capital preservation.
- Restructuring charges of $2.4 million impact near-term financial results.
📋 Key Facts
- Workforce reduction impacting approximately 25 employees (~13% of staff).
- One-time restructuring charges estimated at approximately $2.4 million.
- Charges primarily consist of salaries, severance, and benefits.
- Reduction in force expected to be completed during Q3 2025.
- Company expects current cash/investments to fund operations through 2026.
Alector, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended December 31, 2024. The filing serves as a formal notice that earnings results have been released via press release.
📋 Key Facts
- Report date: February 26, 2025
- Reporting period: Quarter ended December 31, 2024
- The company announced its financial results through a press release (Exhibit 99.1).
- Information under Item 2.02 and 9.01 is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Alector, Inc. announced the termination of its Co-Development and Option Agreement with AbbVie following the failure of the INVOKE-2 Phase 2 clinical trial for AL002. The termination is effective 30 days from January 9, 2025.
🚩 Red Flags
- Loss of a major strategic partner (AbbVie) and all associated collaboration revenue/milestones from that agreement.
- Failure of a lead clinical asset (AL002) to meet primary endpoints in Phase 2 trials, significantly impacting the company's pipeline value.
📋 Key Facts
- AbbVie provided written notice to terminate the TREM2 program on January 9, 2025.
- The INVOKE-2 Phase 2 trial for AL002 failed to meet its primary endpoint regarding safety and efficacy in slowing Alzheimer's disease progression.
- AL002 was the only remaining program under the AbbVie Agreement dated October 16, 2017 (amended Feb 13, 2023).
- The termination of the TREM2 program results in the total termination of the AbbVie Agreement.
- Termination becomes effective 30 days after receipt of the notice.
Alector, Inc. announced a strategic workforce reduction of approximately 17% (41 employees) following disappointing Phase 2 clinical trial results for its AL002 candidate in Alzheimer's disease. The company is also discontinuing the long-term extension of the INVOKE-2 study to align resources with new priorities.
🚩 Red Flags
- Clinical trial setback: Stopping the long-term extension of the INVOKE-2 study due to safety/efficacy results for AL002.
- Significant workforce reduction (17%) indicating a pivot or contraction in operations.
- Restructuring charges of $3.9 million impacting near-term financial statements.
📋 Key Facts
- Workforce reduction impacting approximately 17% of staff (41 employees).
- Discontinuation of the long-term extension of the INVOKE-2 Phase 2 clinical trial for AL002 in early Alzheimer’s disease.
- One-time restructuring charges estimated at approximately $3.9 million, primarily for severance and benefits.
- The company expects to complete the reduction in force during the first half of 2025.
- Management states existing cash and investments are expected to fund operations through 2026.
Alector, Inc. entered into a $50 million senior secured term loan facility with Hercules Capital, Inc., of which $10 million was drawn immediately on November 14, 2024. The funds are intended for working capital and general corporate purposes.
🚩 Red Flags
- High interest rate floor of 8.05% suggests a higher risk profile typical of private credit/non-bank lending.
- The facility is secured by substantially all assets, including IP, which increases the seniority of this debt over equity holders in liquidation scenarios.
- The second $25M tranche is at the 'sole discretion' of Lenders, meaning capital certainty is not 100% guaranteed.
📋 Key Facts
- Total facility amount: Up to $50.0 million in senior secured term loans.
- Tranche structure: First tranche of $25.0M available through June 30, 2026; second tranche of $25.0M at Lender discretion.
- Immediate draw: $10.0 million borrowed on November 14, 2024.
- Interest rate: Greater of prime + 1.05% or 8.05%.
- Repayment terms: Interest-only until December 1, 2026 (with potential 24-month extension based on milestones); maturity date is December 1, 2028.
- Collateral: Substantially all company assets, including intellectual property (subject to existing agreements with AbbVie, Adimab, and Glaxo Wellcome UK).
- Prepayment terms: Includes various prepayment premiums and end-of-term charges ranging from 0.5% to 4.75%.
Alector, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal notice that earnings data is being released via press release.
📋 Key Facts
- Report date: November 6, 2024
- Reporting period: Quarter ended September 30, 2024
- The company announced financial results via a press release (Exhibit 99.1)
- Information under Item 2.02 and 9.01 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Alector, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2024. The filing serves as a formal notice that earnings data is being released via press release.
📋 Key Facts
- Report date: August 7, 2024
- Reporting period: Quarter ended June 30, 2024
- The company's financial results are contained in Exhibit 99.1 (Press Release)
- Information under Item 2.02 and 9.01 is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Alector, Inc. reported the results of its 2024 annual meeting of stockholders held on June 12, 2024. The meeting included the election of three Class III directors and the ratification of Ernst & Young LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on June 12, 2024.
- Three Class III director nominees (Louis J. Lavigne, Jr., Richard H. Scheller, Ph.D., and Mark Altmeyer) were elected to serve until the 2027 annual meeting.
- Stockholders ratified Ernst & Young LLP as independent registered accounting firm for fiscal year ending Dec 31, 2024.
- Say-on-Pay advisory vote regarding executive compensation was approved by stockholders.
Alector, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: May 8, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes an earnings press release as Exhibit 99.1
- Information under Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Exchange Act
Alector, Inc. announced the resignation of director Terry McGuire for personal reasons and the simultaneous appointment of two new directors, Errol De Souza, Ph.D. and Mark Altmeyer, to expand the Board's expertise.
🚩 Red Flags
- None identified; director departure was explicitly stated as not being due to disagreements regarding operations or practices.
📋 Key Facts
- Terry McGuire resigned from the Board effective March 20, 2024; stated resignation is for personal reasons and not due to any disagreement with the Company.
- Errol De Souza, Ph.D. appointed as Class II director on March 19, 2024, joining the Compensation and Audit Committees.
- Mark Altmeyer appointed as Class III director on March 19, 2024, joining the Audit and Corporate Governance and Nominating Committees.
- Board size fluctuated from eight to ten, then settled at nine directors following the resignations/appointments.
- New directors were granted nonstatutory stock options (19,420 shares) and RSUs (41,250 units) with standard vesting schedules.
Alector, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended December 31, 2023. The filing serves as a formal announcement of earnings and incorporates a press release via Exhibit 99.1.
📋 Key Facts
- Report date: February 27, 2024
- Reporting period: Quarter ended December 31, 2023
- The filing includes the announcement of financial results and operations.
- Information under Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Alector, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. to conduct a public offering of common stock. The company expects to raise approximately $75 million in gross proceeds.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 10 million new shares.
📋 Key Facts
- Underwriter: Cantor Fitzgerald & Co.
- Shares to be issued: 10,869,566 shares of common stock
- Price per share: $6.57
- Expected gross proceeds: Approximately $75 million (before discounts and expenses)
- Over-allotment option: Up to 1,630,434 additional shares available for 30 days
- Closing date: Expected January 19, 2024
- Registration basis: Effective Form S-3 (declared effective May 1, 2023)
Alector, Inc. provided a preliminary estimate of its cash, cash equivalents, and short-term investments as of December 31, 2023. The company reports a strong liquidity position with sufficient runway to fund operations into the second half of 2026.
🚩 Red Flags
- Information is preliminary and has not been audited by independent public accounting firm.
📋 Key Facts
- Preliminary cash, cash equivalents, and short-term investments: approximately $549 million as of December 31, 2023.
- Estimated liquidity runway extends into the second half of 2026.
- Financial figures are preliminary, unaudited, and subject to change upon completion of year-end closing processes.